Patents by Inventor Cooper Taylor

Cooper Taylor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMIDAZ0[1,2-A]PYRIMIDINE-5(1 H)-ONES AS WRN INHIBITORS
    Publication number: 20250270218
    Abstract: Disclosed are compounds of Formula (I) and Formula (II), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing, or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: November 20, 2024
    Publication date: August 28, 2025
    Applicant: Incyte Corporation
    Inventors: Stacey SHEPARD, Yanran AI, Joe BARBOSA, Marc DELLER, Nikoo FALAHATPISHEH, Ananda GHOSH, Joe Glenn, JR., Leslie McQUIRTER, Yehao QIU, Cooper TAYLOR, Xiaozhao WANG, Eddy YUE, Guofeng ZHANG
  • IMIDAZ0[1,2-A]PYRIMIDINE-5(1 H)-ONES HAVING A COVALENT WARHEAD AT THE 3-POSITION AS WRN INHIBITORS
    Publication number: 20250270217
    Abstract: Disclosed are compounds of Formula (I) and Formula (II), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing, or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: November 20, 2024
    Publication date: August 28, 2025
    Applicant: Incyte Corporation
    Inventors: Yanran AI, Joe BARBOSA, Huan CHEN, Marc DELLER, Balu D. DHERANGE, Nikoo FALAHATPISHEH, Ananda GHOSH, Joe Glenn, JR., Yong LI, Leslie McQUIRTER, Yehao QIU, Stacey SHEPARD, Cooper TAYLOR, Xiaozhao WANG, Eddy Yue, Guofeng ZHANG, Le ZHAO, Zhitong ZHENG
  • TRICYCLIC COMPOUNDS AS INHIBITORS OF WRN
    Publication number: 20250215006
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing, or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: October 14, 2024
    Publication date: July 3, 2025
    Applicant: Incyte Corporation
    Inventors: Yanran Ai, Joe Barbosa, Ananda Ghosh, Marc D. Deller, Joe Glenn, JR., Leslie McQuirter, Yehao Qiu, Lixin Shao, Stacey Shepard, Cooper Taylor, Xiaozhao Wang, Eddy Yue, Guofeng Zhang
  • TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS
    Publication number: 20250122170
    Abstract: The present application provides tricyclic urea compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
    Type: Application
    Filed: July 31, 2024
    Publication date: April 17, 2025
    Inventors: Cooper Taylor, Yanran Ai, Chunhong He, Ke Zhang, Zhitong Zheng, Eddy W. Yue
  • Tricyclic urea compounds as JAK2 V617F inhibitors
    Patent number: 12084430
    Abstract: The present application provides tricyclic urea compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
    Type: Grant
    Filed: March 16, 2023
    Date of Patent: September 10, 2024
    Assignee: Incyte Corporation
    Inventors: Cooper Taylor, Yanran Ai, Chunhong He, Ke Zhang, Eddy W. Yue
  • TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS
    Publication number: 20230295124
    Abstract: The present application provides tricyclic urea compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
    Type: Application
    Filed: March 16, 2023
    Publication date: September 21, 2023
    Inventors: Cooper Taylor, Yanran Ai, Chunhong He, Ke Zhang, Zhitong Zheng, Eddy W. Yue